**e-table 3. Correlation of quality measures with estimates of treatment effects assessment of the trials**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Ahmed *et al.57*** | **Babalola *et al.60*** | **Biber *et al61*** | **Bukhari *et al63*** | **Carvallo *et al.65*** | **Chaccour *et al.66*** | **Chachar *et al.67***  | **Chahla *et al.68*** | **Chowdhury *et al.35*** | **Elalfy et al*69*** |
| Study question well defined in introduction /methods | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Study question well defined anywhere in the article | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Placebo control | Yes | Yes | Yes | No | No | Yes | No | No | No | No |
| Appropriate outcome studied | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Multicenter study | N/D | N/D | Yes | No | No | No | No | Yes | No | No |
| Study country | Bangladesh | Nigeria | Israel | Pakistan | Argentina | Spain | Pakistan | Argentina | Bangladesh | Egypt |
| Adequate selection criteria | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
| Randomization methods described | No | No | Yes | Yes | N/A | Yes | Yes | Yes | Yes | N/A |
| Central randomization site | N/D | N/D | Yes | N/A | N/A | Yes | N/A | Yes | N/A | N/A |
| Allocation concealment | Yes | Yes | Yes | No | N/A | Yes | No | No | No | No |
| Patients blinded | Yes | Yes | Yes | No | No | Yes | No | No | No | No |
| Caregivers blinded | Yes | Yes | Yes | No | No | Yes | No | No | No | No |
| Outcome assessors blinded | N/D | N/D | Yes | No | No | N/D | N/D | No | N/D | N/D |
| Data analysts blinded | N/D | N/D | Yes | N/D | No | N/D | N/D | Yes | N/D | N/D |
| Double blinded | Yes | Yes | Yes | No | No | Yes | No | No | No | No |
| Vital statistical measures | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Statistician author or acknowledged | No | No | Yes | No | No | No | No | Yes | Yes | Yes |
| Intention-to-treat analysis | No | No | No | No | No | N/A | No | No | No | No |
| Power calculation reported | No | No | Yes | No | No | Yes | No | No | No | No |
| Stopping rules described | No | No | No | No | No | No | No | No | No | No |
| Baseline characteristics reported | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Groups similar at baseline | Yes | No | Yes | N/D | N/A | No | No | No | No | No |
| Confounders accounted for | No | Yes | No | No | No | Yes | No | Yes | No | No |
| Percentage dropouts | Yes | Yes | No | Yes | N/A | Yes | N/A | Yes | N/A | Yes |
| Reasons for dropout given | Yes | Yes | No | Yes | N/A | N/A | N/A | N/A | N/A | No |
| Findings support conclusion | Yes  | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |

**N/A, Not applicable; N/D, Not defined**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Espitia-Hernandez *et al.70*** | **Galan et al*71*** | **Gonzalez et al*72*** | **Gorial *et al. 32*** | **Hashim *et al. 74*** | **Huvemec trial*76*** | **Krolewiecki *et al.80*** | **Kishoria *et al.79***  |
| Study question well defined in introduction /methods | Yes | Yes | Yes | Yes | Yes | N/A | Yes | Yes |
| Study question well defined anywhere in the article | Yes | Yes | Yes | Yes | Yes | N/A | Yes | Yes |
| Placebo control | No | No | Yes | No | No | Yes | No | No |
| Appropriate outcome studied | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Multicenter study | No | No | No | No | No | Yes | Yes | No |
| Study country | Mexico | Brazil | Mexico | Iraq | Iraq | Bulgaria | Argentina | India |
| Adequate selection criteria | Yes | Yes | Yes | Yes | Yes | N/D | Yes | Yes |
| Randomization methods described | Yes | Yes | Yes | N/D | Yes | No | Yes | Yes |
| Central randomization site | N/A | N/A | N/A | N/A | N/A | N/D | Yes | N/A |
| Allocation concealment | No | Yes | N/D | No | No | Yes | No | Yes |
| Patients blinded | No | Yes | Yes | No | No | Yes | No | No |
| Caregivers blinded | No | Yes | Yes | No | No | Yes | No | No |
| Outcome assessors blinded | No | N/D | N/D | N/D | N/D | N/D | Yes | N/D |
| Data analysts blinded | No | N/D | N/D | N/D | N/D | N/D | N/D | N/D |
| Double blinded | No | Yes | Yes | No | No | Yes | No | No |
| Vital statistical measures | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Statistician author or acknowledged | No | No | No | No | No | N/A | Yes | No |
| Intention-to-treat analysis | No | Yes | No | No | No | N/D | Yes | No |
| Power calculation reported | No | Yes | Yes | Yes | No | No | Yes | No |
| Stopping rules described | No | No | No | No | No | No | No | Yes |
| Baseline characteristics reported | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Groups similar at baseline | No | No | No | Yes | Yes | N/D | No | No |
| Confounders accounted for | No | No | No | Yes | Yes | N/D | Yes | No |
| Percentage dropouts | N/A | Yes | N/A | N/A | N/A | No | Yes | Yes |
| Reasons for dropout given | N/A | Yes | N/A | N/A | N/A | No | Yes | N/A |
| Findings support conclusion | Yes | Yes | Yes | Yes | Yes | N/A | Yes | Yes |

 **e-table 3. Correlation of quality measures with estimates of treatment effects assessment of the trials continued**

**N/A, Not applicable; N/D, Not defined**

**e-table 3. Correlation of quality measures with estimates of treatment effects assessment of the trials continued**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Lima Morales *et al. 43*** | **Lopez-Medina *et al.81***  | **Mahmud *et al. 45*** | **Mohan *et al.83*** | **Niaee *et al. 44*** | **Okumus *et al. 88*** | **Podder et al87** | **Pott-Junior *et al.89*** | **Ravikirti *et al.78*** | **Samaha et al47** | **Shahbaznejad *et al.91*** |
| Study question well defined in introduction /methods | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Study question well defined anywhere in the article | Yes | Yes | Yes | Yes | Yes | N/A | Yes | Yes | Yes | Yes | Yes |
| Placebo control | No | Yes | Yes | Yes | Yes  | No | No | No | Yes | Yes | N/D |
| Appropriate outcome studied | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Multicenter study | Yes\* | No | No | No | Yes | Yes | No | No | No | N/D | Yes |
| Study country | Mexico | Colombia | Bangladesh | India | Iran | Turkey | Bangladesh | Brazil | India | Lebanon | Iran |
| Adequate selection criteria | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Randomization methods described | N/A | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Central randomization site | N/A | N/A | N/A | N/A | Yes | No | N/A | N/A | N/A | N/D | N/D |
| Allocation concealment | No | Yes | Yes | Yes | Yes | No | No | No | Yes | No | Yes |
| Patients blinded | No | Yes | Yes | Yes | Yes | No | No | No | Yes | No | Yes |
| Caregivers blinded | No | Yes | Yes | Yes | Yes | No | No | No | Yes | N/D | Yes |
| Outcome assessors blinded | N/D | N/D | N/D | Yes | N/D | N/D | N/D | N/D | N/D | N/D | N/D |
| Data analysts blinded | N/D | N/D | N/D | Yes | N/D | N/D | N/D | N/D | N/D | N/D | N/D |
| Double blinded | No | Yes | Yes | Yes | Yes | No | No | No | Yes | No | Yes |
| Vital statistical measures | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes  | Yes | Yes |
| Statistician author or acknowledged | No | Yes | No | No | No | No | No | No | Yes | No | Yes |
| Intention-to-treat analysis | No | No | Yes | Yes | Yes | No | Yes | No | No | No | No |
| Power calculation reported | No | Yes | Yes | No | Yes | Yes | No | No | Yes | Yes | No |
| Stopping rules described | No | Yes | No | No | No | No | No | No | No | No | No |
| Baseline characteristics reported | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Groups similar at baseline | No | No | No | Yes | N/D | No | Yes | No | Yes | Yes | No |
| Confounders accounted for | Yes | Yes | N/D | Yes | N/D | N/D | N/D | No | No | Yes | No |
| Percentage dropouts | Yes | N/A | Yes | Yes | N/A | Yes | N/A | Yes | Yes | N/A | Yes |
| Reasons for dropout given | Yes | N/A | Yes | Yes | N/A | No | N/A | No | Yes | N/A | No |
| Findings support conclusion | Yes | Yes | N/A | Yes | Yes | N/A | Yes | Yes | Yes | Yes | Yes |

**N/A, Not applicable; N/D, Not defined**

**e-table 3. Correlation of quality measures with estimates of treatment effects assessment of the trials continued**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Reference** | **Abd‐Elsalam *et al94*** | **Aref *et al95*** | **Vallejos *et al96*** | **Hazan *et al97*** |
| Study question well defined in introduction /methods | Yes | Yes | Yes | Yes |
| Study question well defined anywhere in the article | Yes | Yes | Yes | Yes |
| Placebo control | No | No | Yes | No |
| Appropriate outcome studied | Yes | Yes | Yes | Yes |
| Multicenter study | Yes | No | Yes | No |
| Study country | Egypt | Egypt | Argentina | USA |
| Adequate selection criteria | Yes | Yes | Yes | Yes |
| Randomization methods described | Yes | No | Yes | N/A |
| Central randomization site | No | N/A | Yes | N/A |
| Allocation concealment | Yes | N/D | Yes | No |
| Patients blinded | No | No | Yes | No |
| Caregivers blinded | No | No | Yes | No |
| Outcome assessors blinded | N/D | No | Yes | N/D |
| Data analysts blinded | N/D | N/D | Yes | N/D |
| Double blinded | No | No | Yes | No |
| Vital statistical measures | Yes | Yes | Yes | Yes |
| Statistician author or acknowledged | Yes | No | Yes | No |
| Intention-to-treat analysis | Yes | N/D | Yes | No |
| Power calculation reported | Yes | No | Yes | No |
| Stopping rules described | No | No | Yes | No |
| Baseline characteristics reported | Yes | Yes | Yes | Yes |
| Groups similar at baseline | Yes | No | Yes | N/A |
| Confounders accounted for | N/D | N/D | Yes | No |
| Percentage dropouts | Yes | Yes | Yes | Yes |
| Reasons for dropout given | N/A | N/A | N/A | Yes |
| Findings support conclusion | Yes | Yes | Yes | Yes |

**N/A, Not applicable; N/D, Not defined**